Inflammatory Cytokine ExpressionNCT07367451
Effects of Propolis Flavonoids on TLR4 Signaling and Inflammation in Human PDLSCs In Vitro
An observational study of Inflammatory Cytokine Expression, run by Cairo University.
Trial summary
This in-vitro study evaluated the effects of a flavonoid-rich propolis extract on Toll-like receptor 4 (TLR4) signaling and inflammatory cytokine expression in human periodontal ligament stem cells (PDLSCs). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Inflammatory Cytokine Expression
- What is being tested?
- Flavonoid extract from propolis and no medication added
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 25 Jan 2026to 10 Feb 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: in vitro study
Who may be able to join
- invitro study on Human Periodontal Ligament Stem Cells
Who cannot join
- none
About this study
Official title: Effect of Propolis-Derived Flavonoid Extract on TLR4 Signaling and Inflammatory Cytokine Expression in Human Periodontal Ligament Stem Cells (PDLSCs): An In-Vitro Study
This in-vitro study evaluated the effects of a flavonoid-rich propolis extract on Toll-like receptor 4 (TLR4) signaling and inflammatory cytokine expression in human periodontal ligament stem cells (PDLSCs). PDLSCs were treated with propolis flavonoids under baseline conditions and following lipopolysaccharide (LPS)-induced inflammation, with untreated cells serving as controls. TLR4 gene expression was analyzed using PCR, while levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) were quantified by ELISA. Cell viability and cytotoxicity at different extract concentrations were assessed using the MTT assay. The study aimed to determine the immunomodulatory and cytocompatible potential of propolis flavonoids in regulating inflammatory responses in PDLSCs.
- Conditions
- Inflammatory Cytokine Expression
- Being tested
- Flavonoid extract from propolis, no medication added
- Keywords
- TLR4, flavonoid-rich propolis, Periodontal ligament, stem cells
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Flavonoid extract from propolisDrug
Preparation of Propolis Flavonoid Extract
Concentrations for testing:
5 µg/mL 10 µg/mL 20 µg/mL
no medication addedOther
No medication will be added to the second group
| Study group | Role | What they receive |
|---|---|---|
| Isolated PDLSCs, and adding Flavonoid extract from propolis | Not described Receives: Drug: Flavonoid extract from propolis | |
| Isolated PDLSCs, no material added | Not described Receives: Other: no medication added |
What is being measured
The primary outcome is the main question the study is designed to answer.
TLR4 expression
To evaluate the expression of TLR4 in PDLSCs after treatment with propolis flavonoid extract.
Measured: 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2026
- Study start25 Jan 2026 (estimated)
- Primary completion30 Jan 2026 (estimated)
- Study completion10 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Inflammatory Cytokine ExpressionStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ghada Adayil, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07367451
- Sponsor's protocol ID
- 12/2025
- Status last verified
- Jan 2026
- First submitted
- 18 Jan 2026
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Propolis-Derived Flavonoid Extract on TLR4 Signaling and Inflammatory Cytokine Expression in Human Periodontal Ligament Stem Cells (PDLSCs): An In-Vitro Study
- ClinicalTrials.gov ID
- NCT07367451
- Acronym / sponsor ID
- 12/2025
- Conditions
- Inflammatory Cytokine Expression
- Keywords
- TLR4, flavonoid-rich propolis, Periodontal ligament, stem cells
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 25 Jan 2026 (estimated)
- Primary completion
- 30 Jan 2026 (estimated)
- Study completion
- 10 Feb 2026 (estimated)
- First posted
- 26 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This in-vitro study evaluated the effects of a flavonoid-rich propolis extract on Toll-like receptor 4 (TLR4) signaling and inflammatory cytokine expression in human periodontal ligament stem cells (PDLSCs). PDLSCs were treated with propolis flavonoids under baseline conditions and following lipopolysaccharide (LPS)-induced inflammation, with untreated cells serving as controls. TLR4 gene expression was analyzed using PCR, while levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) were quantified by ELISA. Cell viability and cytotoxicity at different extract concentrations were assessed using the MTT assay. The study aimed to determine the immunomodulatory and cytocompatible potential of propolis flavonoids in regulating inflammatory responses in PDLSCs.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Isolated PDLSCs, and adding Flavonoid extract from propolis | – | Drug: Flavonoid extract from propolis |
| Isolated PDLSCs, no material added | – | Other: no medication added |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- in vitro study
Key inclusion criteria (1 listed)
- invitro study on Human Periodontal Ligament Stem Cells
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Flavonoid extract from propolisPreparation of Propolis Flavonoid Extract Concentrations for testing: 5 µg/mL 10 µg/mL 20 µg/mL | Drug | Isolated PDLSCs, and adding Flavonoid extract from propolis |
| no medication addedNo medication will be added to the second group | Other | Isolated PDLSCs, no material added |
Primary outcome
TLR4 expression
Time frame: 48 hours
To evaluate the expression of TLR4 in PDLSCs after treatment with propolis flavonoid extract.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
Related trials for Inflammatory Cytokine Expression
Not yet recruiting
Assessment of GARP Expression in Acute and Chronic Coronary Syndrome
Atheroma; Heart
Active, not recruiting
Evaluation of Pulpal Biomarkers in Vital Pulp Therapy
Reversible Pulpitis, Irreversible Pulpitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Inflammatory Cytokine Expression, run by Cairo University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
TLR4 expression (time frame: 48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.